Lung Clearance Measurement to Determine Pre-clinical Airway Involvement in Scleroderma Patients Without Lung Disease as a Risk Factor for Developing ILD

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

This National Jewish Health (NJH) Investigator Initiated pilot study funded by the Shah Foundation will prospectively perform a non invasive lung function test called Lung Clearance Index (LCI) to determine if 50 scleroderma patients without evidence of lung disease who have evidence of small airway inflammation or impairment to airflow are more likely to develop ILD than those with normal vales.50 subjects will be enrolled from the Rheumatology practice at NJH and followed with phone interviews or Electronic Medical Record (EMR) record review yearly times 5 to determine if they have subsequently developed evidence of ILD or pulmonary artery hypertension.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Maximum Age: 75
Healthy Volunteers: f
View:

• Confirmed diagnosis of systemic sclerosis (SSC) by an NJH Rheumatologist

• age 21-75

• No evidence of Scleroderma related Lung disease (ILD)

• Able to comprehend and sign an Institutional Review Board (IRB) approved consent form.

Locations
United States
Colorado
National Jewish Health
RECRUITING
Denver
Contact Information
Primary
Richard T meehan, MD
meehanr@njhealth.org
303 3981-1475
Backup
Mary Gill, RN
gillm@njhealth.org
720 936-9619
Time Frame
Start Date: 2021-01-04
Estimated Completion Date: 2026-01-15
Participants
Target number of participants: 50
Treatments
LCI testing
LCI testing will be performed on all study subjects
Related Therapeutic Areas
Sponsors
Leads: National Jewish Health

This content was sourced from clinicaltrials.gov